Z Squared Inc. quarterly report, Q3 FY2024

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (Note: Input metadata referenced "Z Squared Inc.", but the filing text identifies the registrant as Coeptis Therapeutics Holdings, Inc., trading as COEP).

Reporting Period: Quarterly period ended September 30, 2024 (Form 10-Q).

Business Overview: Coeptis is a pharmaceutical company focused on acquiring and developing drug products and technologies, primarily in auto-immune and oncology markets. The company operates through wholly-owned subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences, Inc., and GEAR Therapeutics, Inc. It has no commercial product sales currently and relies on capital raising and strategic partnerships to fund operations.

Key Financial Metrics

Metric Three Months Ended Sept 30, 2024 Nine Months Ended Sept 30, 2024 As of Sept 30, 2024
Revenue $0 $0 N/A
Net Loss $(1,828,914) $(7,865,647) N/A
Operating Expenses $2,141,789 $7,892,274 N/A
Cash and Cash Equivalents N/A N/A $1,137,453
Total Assets N/A N/A $8,955,984
Total Liabilities N/A N/A $3,973,567
Stockholders' Equity N/A N/A $4,982,417
Notes Payable (Current) N/A N/A $1,553,929

Loss Per Share: $(0.05) for the three months ended September 30, 2024; $(0.21) for the nine months ended September 30, 2024.

Material Changes vs. Prior Period

  • Operating Expenses: Decreased significantly from $7,901,220 in the three months ended September 30, 2023, to $2,141,789 in the current quarter. This reduction is primarily attributed to lower professional services expenses related to equity transactions.
  • Net Loss: Improved from $(6,350,494) in the prior year quarter to $(1,828,914) in the current quarter.
  • Debt Status: Several convertible notes payable are in default as of September 30, 2024, including notes to Purple Biotech and an unrelated third party. However, a $1,500,000 note was replaced by a new agreement in November 2024 (subsequent event).
  • Investments: Total assets increased from $4.57 million (Dec 31, 2023) to $8.96 million (Sept 30, 2024), driven largely by the recognition of $5.69 million in investments received in exchange for subscription receivables.

Guidance, Outlook, and Risks

  • Going Concern: The filing states that the company's accumulated deficit of $95.2 million and net loss for the nine months ended September 30, 2024, raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt sales.
  • Revenue Outlook: Management does not expect to generate significant revenue for at least the next two years while drug development continues.
  • Capital Raising:
    • Series A Preferred Stock: Completed three closings in 2024, raising approximately $5.8 million total. A final closing is anticipated in November 2024.
    • SEPA: On November 1, 2024, the company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the sale of up to $20 million of common stock.
    • Yorkville Note: Concurrent with the SEPA, the company received a $1.3 million convertible promissory note.
  • Risks: Risks include the failure to secure additional funding, delays in product development, and the potential inability to commercialize target products. The company also faces risks related to the default status of certain debt instruments.

Investor Verification Checklist

  • Debt Default Status: Verify the current status of the defaulted notes payable (Purple Biotech and third-party notes) and the terms of the new Yorkville Note replacing the January 2024 note.
  • Liquidity Runway: Assess the sufficiency of the $1.14 million cash balance against operating expenses of ~$2.1 million per quarter to determine the immediate need for the anticipated Series A final closing or SEPA draws.
  • Investment Valuation: Review the valuation and liquidity of the $5.69 million in investments (shares of privately held companies) recorded in exchange for subscription receivables.
  • Series A Terms: Confirm the final closing details of the Series A Preferred Stock offering and the specific conversion rights and liquidation preferences.
  • Going Concern Mitigation: Monitor the execution of the SEPA and the ability to raise the necessary capital to sustain operations beyond the current cash position.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.